Quantcast

Latest HBV Stories

2014-09-18 08:29:39

MILFORD, Mass., Sept. 18, 2014 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RNA viruses, today announced a research collaboration with the National Institutes of Health (NIH) for animal testing of the Company's lead compound, SB 9200, against multiple viral pathogens, classified as "Special Pathogens," against which currently there are no effective antiviral therapies. SB 9200, derived...

2014-09-04 08:29:50

Pharmacokinetics, Safety and Tolerability of NVR-1221 Support Advancement to Phase 1b Clinical Studies in Patients with Chronic HBV Infection DOYLESTOWN, Pa., Sept. 4, 2014 /PRNewswire/ -- Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced successful completion of a Phase 1a clinical study of NVR-1221. The results for the Phase 1a clinical study...

2014-08-26 08:30:57

DOYLESTOWN, Pa., Aug. 26, 2014 /PRNewswire/ -- Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced that Roger J. Pomerantz, M.D., F.A.C.P., was appointed the Chair of its Scientific Advisory Board (SAB). In this role he will also function as a Senior Advisor to the Company. "We are thrilled to have Roger join our SAB as Chair," said Christian Schade,...

2014-07-02 08:26:15

CARLSBAD, Calif., July 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline. We look forward to continuing to advance...

2014-05-20 23:18:15

In its May 2014 survey, polyDNA found that 36% of respondents wanted to know what complications can arise from a hepatitis B infection. polyDNA reviews the literature, and recommends Gene-Eden-VIR and Novirin, which have a formula proven to reduce viral symptoms in two post-marketing clinical studies. Rochester, NY (PRWEB) May 20, 2014 In polyDNA’s latest survey, 36% of participants wanted to know what complications can arise from a hepatitis B infection. The answer is that a long-term,...

2014-05-20 04:21:04

GENEVA, May 20, 2014 /PRNewswire/ -- The International Federation of Pharmaceutical Manufacturers and Associations [http://www.ifpma.org ] (IFPMA) has published today a new report and recommendations on Hepatitis, encouraging a comprehensive approach to fighting this silent epidemic. Titled "Towards a Sustainable, Intersectoral Approach to Viral Hepatitis [http://www.ifpma.org/fileadmin/content/Publication/2014/IFPMA_Viral_Hepatitis_May2014.pdf ] ", the report is meant to...

2014-05-12 08:30:57

MILFORD, Mass., May 12, 2014 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B (HBV) and Hepatitis C (HCV) infections, at the 27th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the...

2014-05-08 08:32:52

DOYLESTOWN, Pa., May 8, 2014 /PRNewswire/ -- Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced that it initiated a Phase 1a clinical study of NVR-1221. The Phase 1a clinical study is designed to assess the pharmacokinetic profile and dose-related safety and tolerability of NVR-1221 in healthy volunteers. "We are thrilled to begin the clinical development...

2014-04-14 12:33:05

CALGARY, April 14, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Combined anti-viral and anti-tumour therapy for virus-associated liver cancer," covered preclinical research into the treatment of hepatocellular...

2014-04-14 11:03:19

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB). "Together these ground-breaking data will go a long way to influencing future CHB treatment guidelines," said EASL's Educational Councillor Professor Cihan Yurdaydin from the Department of Gastroenterology, University of...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'